4.1. Therapeutic indications

VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,

- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and

- who have no satisfactory treatment options (see sections 4.4 and 5.1).

4.2. Posology and method of administration

Treatment with VITRAKVI should be initiated by physicians experienced in the administration of anticancer therapies.

The presence of an NTRK gene fusion in a tumour specimen should be confirmed by a validated test prior to initiation of treatment with VITRAKVI.

Posology

Adults

The recommended dose in adults is 100 mg larotrectinib twice daily, until disease progression or until unacceptable toxicity occurs.

Paediatric population

Dosing in paediatric patients is based on body surface area (BSA). The recommended dose in paediatric patients is 100 mg/m2 larotrectinib twice daily with a maximum of 100 mg per dose until disease progression or until unacceptable toxicity occurs.

For paediatric patients from birth to less than 3 months the recommended starting dose is 50 mg/m2 twice daily (see section 5.2).

Missed dose

If a dose is missed, the patient should not take two doses at the same time to make up for a missed dose. Patients should take the next dose at the next scheduled time. If the patient vomits after taking a dose, the patient should not take an additional dose to make up for vomiting.

Dose modification

For all grade 2 adverse reactions, continued dosing may be appropriate, though close monitoring to ensure no worsening of the toxicity is advised.

For all grade 3 or 4 adverse reactions not referring to liver function test abnormalities:

- VITRAKVI should be withheld until the adverse reaction resolves or improves to baseline or grade 1. Resume at the next dose modification if resolution occurs within 4 weeks.

- VITRAKVI should be permanently discontinued if an adverse reaction does not resolve within 4 weeks.

The recommended dose modifications for VITRAKVI for adverse reactions are provided in Table 1.

Table 1: Recommended dose modifications for VITRAKVI for adverse reactions

Dose modification

Adult and paediatric patients with body surface area of at least 1.0 m2

Paediatric patients aged 3 months or older with body surface area less than 1.0 m2

Paediatric patients aged less than 3 months

First

75 mg twice daily

75 mg/m2 twice daily

25 mg/m2 twice daily

Second

50 mg twice daily

50 mg/m2 twice daily

-

Third

100 mg once daily

25 mg/m2 twice dailya

-

a Paediatric patients on third dose modification at 25 mg/m² twice daily should remain on this dose (25 mg/m2 twice daily) even if body surface area increases during the treatment.

VITRAKVI should be permanently discontinued in patients who are unable to tolerate VITRAKVI after three dose modifications.

The recommended dose modifications in case of liver function tests abnormalities during treatment with VITRAKVI are provided in Table 2.

Table 2: Recommended dose modifications and management for VITRAKVI for liver function test abnormalities

Laboratory parameters

Recommended measures

Grade 2 ALT and/or AST (>3x ULN and ≤5x ULN)

- Conduct serial laboratory evaluations frequently after the observation of grade 2 toxicity, until resolved, to establish whether a dose interruption or reduction is required.

Grade 3 ALT and/or AST (>5x ULN and ≤20x ULN)

or

Grade 4 ALT and/or AST (>20x ULN), with bilirubin <2x ULN

- Withhold treatment until the adverse reaction resolves or improves to baseline. Monitor liver function frequently until resolution or return to baseline. Permanently discontinue treatment if an adverse reaction does not resolve.

- Resume at the next dose modification if adverse reactions resolve. Treatment should only be resumed in patients where the benefit outweighs the risk.

- Permanently discontinue treatment if a grade 4 ALT and/or AST elevation occurs after resuming treatment.

ALT and/or AST ≥3x ULN with bilirubin ≥2x ULN

- Withhold treatment and monitor liver function frequently until resolution or return to baseline.

- Consider permanent treatment discontinuation.

- Treatment should only be resumed in patients where the benefit outweighs the risk.

- If resumed, start at the next lower dose. Monitor liver function frequently upon restart.

- Permanently discontinue treatment if adverse reaction recurs after resuming treatment.

ALT Alanine aminotransferase

AST Aspartate aminotransferase

ULN upper limit of normal

Special populations

Elderly

No dose adjustment is recommended in elderly patients (see section 5.2).

Hepatic impairment

The starting dose of VITRAKVI should be reduced by 50% in patients with moderate (Child‑Pugh B) to severe (Child‑Pugh C) hepatic impairment. No dose adjustment is recommended for patients with mild hepatic impairment (Child‑Pugh A) (see section 5.2).

Renal impairment

No dose adjustment is required for patients with renal impairment (see section 5.2).

Co‑administration with strong CYP3A4 inhibitors

If co‑administration with a strong CYP3A4 inhibitor is necessary, the VITRAKVI dose should be reduced by 50%. After the inhibitor has been discontinued for 3 to 5 elimination half‑lives, VITRAKVI should be resumed at the dose taken prior to initiating the CYP3A4 inhibitor (see section 4.5).

Method of administration

VITRAKVI is for oral use.

VITRAKVI is available as a capsule or oral solution with equivalent oral bioavailability and may be used interchangeably.

The patient should be advised to swallow the capsule whole with a glass of water. Due to the bitter taste, the capsule should not be opened, chewed or crushed.

The capsules can be taken with or without food but should not be taken with grapefruit or grapefruit juice.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Efficacy across tumour types

The benefit of VITRAKVI has been established in single arm trials encompassing a relatively small sample of patients whose tumours exhibit NTRK gene fusions. Favourable effects of VITRAKVI have been shown on the basis of overall response rate and response duration in a limited number of tumour types. The effect may be quantitatively different depending on tumour type, as well as on concomitant genetic alterations (see section 5.1). For these reasons, VITRAKVI should only be used if there are no treatment options for which clinical benefit has been established, or where such treatment options have been exhausted (i.e., no satisfactory treatment options).

Neurologic reactions

Neurologic reactions including dizziness, gait disturbance and paraesthesia were reported in patients receiving larotrectinib (see section 4.8). For the majority of neurologic reactions, onset occurred within the first three months of treatment. Withholding, reducing, or discontinuing VITRAKVI dosing should be considered, depending on the severity and persistence of these symptoms (see section 4.2).

Hepatotoxicity

Abnormalities of liver function tests including increased ALT, AST, alkaline phosphatase (ALP) and bilirubin have been observed in patients receiving larotrectinib (see section 4.8). The majority of ALT and AST increases occurred within 3 months of starting treatment. Cases of hepatotoxicity with increases in ALT and/or AST of grade 2, 3 or 4 severity and increases in bilirubin ≥ 2x ULN have been reported.

In patients with hepatic transaminase elevations, withhold, modify dose or permanently discontinue VITRAKVI based on the severity (see section 4.2).

Liver function including ALT, AST, ALP and bilirubin should be monitored before the first dose, then every 2 weeks during the first month of treatment, then monthly for the next 6 months of treatment, then periodically during treatment. In patients who develop transaminase elevations, more frequent testing is needed (see section 4.2).

Co‑administration with CYP3A4/P‑gp inducers

Avoid co‑administration of strong or moderate CYP3A4/P‑gp inducers with VITRAKVI due to a risk of decreased exposure (see section 4.5).

Contraception in female and male

Women of childbearing potential must use highly effective contraception while taking VITRAKVI and for at least one month after stopping treatment (see sections 4.5 and 4.6).

Males of reproductive potential with a non‑pregnant woman partner of childbearing potential should be advised to use highly effective contraception during treatment with VITRAKVI and for at least one month after the final dose (see section 4.6).

4.5. Interaction with other medicinal products and other forms of interaction

Effects of other agents on larotrectinib

Effect of CYP3A, P‑gp and BCRP inhibitors on larotrectinib

Larotrectinib is a substrate of cytochrome P450 (CYP) 3A, P‑glycoprotein (P‑gp) and breast cancer resistance protein (BCRP). Co‑administration of VITRAKVI with strong or moderate CYP3A inhibitors, P‑gp and BCRP inhibitors (e.g. atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole or grapefruit) may increase larotrectinib plasma concentrations (see section 4.2).

Clinical data in healthy adult subjects indicate that co‑administration of a single 100 mg VITRAKVI dose with itraconazole (a strong CYP3A inhibitor and P‑gp and BCRP inhibitor) 200 mg once daily for 7 days increased larotrectinib Cmax and AUC by 2.8‑fold and 4.3‑fold, respectively.

Clinical data in healthy adult subjects indicate that co‑administration of a single 100 mg VITRAKVI dose with a single dose of 600 mg rifampicin (a P‑gp and BCRP inhibitor) increased larotrectinib Cmax and AUC by 1.8‑fold and 1.7‑fold, respectively.

Effect of CYP3A and P‑gp inducers on larotrectinib

Co‑administration of VITRAKVI with strong or moderate CYP3A inducers and strong P‑gp inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, or St. John's Wort) may decrease larotrectinib plasma concentrations and should be avoided (see section 4.4).

Clinical data in healthy adult subjects indicate that co‑administration of a single 100 mg VITRAKVI dose with rifampicin (a strong CYP3A and P‑gp inducer) 600 mg once daily for 11 days decreased larotrectinib Cmax and AUC by 71% and 81%, respectively. No clinical data is available on the effect of a moderate inducer, but a decrease in larotrectinib exposure is expected.

Effects of larotrectinib on other agents

Effect of larotrectinib on CYP3A substrates

Clinical data in healthy adult subjects indicate that co‑administration of VITRAKVI (100 mg twice daily for 10 days) increased the Cmax and AUC of oral midazolam 1.7‑fold compared to midazolam alone, suggesting that larotrectinib is a weak inhibitor of CYP3A.

Exercise caution with concomitant use of CYP3A substrates with narrow therapeutic range (e.g. alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, or tacrolimus) in patients taking VITRAKVI. If concomitant use of these CYP3A substrates with narrow therapeutic range is required in patients taking VITRAKVI, dose reductions of the CYP3A substrates may be required due to adverse reactions.

Effect of larotrectinib on CYP2B6 substrates

In vitro studies indicate that larotrectinib induces CYP2B6. Co‑administration of larotrectinib with CYP2B6 substrates (e.g. bupropion, efavirenz) may decrease their exposure.

Effect of larotrectinib on other transporter substrates

In vitro studies indicate that larotrectinib is an inhibitor of OATP1B1. No clinical studies have been performed to investigate interactions with OATP1B1 substrates. Therefore, it cannot be excluded whether co‑administration of larotrectinib with OATP1B1 substrates (e.g. valsartan, statins) may increase their exposure.

Effect of larotrectinib on substrates of PXR regulated enzymes

In vitro studies indicate that larotrectinib is a weak inducer of PXR regulated enzymes (e.g. CYP2C family and UGT). Co‑administration of larotrectinib with CYP2C8, CYP2C9 or CYP2C19 substrates (e.g. repaglinide, warfarin, tolbutamide or omeprazole) may decrease their exposure.

Hormonal contraceptives

It is currently unknown whether larotrectinib may reduce the effectiveness of systemically acting hormonal contraceptives. Therefore, women using systemically acting hormonal contraceptives should be advised to add a barrier method.

4.6. Fertility, pregnancy and lactation

Women of childbearing potential / Contraception in males and females

Based on the mechanism of action, foetal harm cannot be excluded when administering larotrectinib to a pregnant woman. Women of childbearing potential should have a pregnancy test prior to starting treatment with VITRAKVI.

Women of reproductive potential should be advised to use highly effective contraception during treatment with VITRAKVI and for at least one month after the final dose. As it is currently unknown whether larotrectinib may reduce the effectiveness of systemically acting hormonal contraceptives, women using systemically acting hormonal contraceptives should be advised to add a barrier method.

Males of reproductive potential with a non‑pregnant woman partner of childbearing potential should be advised to use highly effective contraception during treatment with VITRAKVI and for at least one month after the final dose.

Pregnancy

There are no data from the use of larotrectinib in pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

As a precautionary measure, it is preferable to avoid the use of VITRAKVI during pregnancy.

Breast‑feeding

It is unknown whether larotrectinib/metabolites are excreted in human milk.

A risk to newborns/infants cannot be excluded.

Breast‑feeding should be discontinued during treatment with VITRAKVI and for 3 days following the final dose.

Fertility

There are no clinical data on the effect of larotrectinib on fertility. No relevant effects on fertility were observed in repeat‑dose toxicity studies (see section 5.3).

4.7. Effects on ability to drive and use machines

VITRAKVI has a moderate influence on the ability to drive and use machines. Dizziness and fatigue have been reported in patients receiving larotrectinib, mostly grade 1 and 2 during the first 3 months of treatment. This may influence the ability to drive and use machines during this time period. Patients should be advised not to drive and use machines, until they are reasonably certain VITRAKVI therapy does not affect them adversely (see section 4.4).

4.8. Undesirable effects

Summary of the safety profile

The most common adverse drug reactions (≥ 20%) of VITRAKVI in order of decreasing frequency were increased ALT (36%), increased AST (33%), vomiting (30%), anaemia (28%), constipation (28%), diarrhoea (27%), nausea (24%), fatigue (23%), and dizziness (20%).

The majority of adverse reactions were grade 2 or 3. Grade 4 was the highest reported grade for adverse reactions neutrophil count decreased (2%), ALT increased (1%), AST increased, leukocyte count decreased, platelet count decreased, muscular weakness and blood alkaline phosphatase increased (each in < 1%). The highest reported grade was grade 3 for adverse reactions anaemia (7%), weight increased (6%), diarrhoea (4%), gait disturbance and vomiting (each 1%), and fatigue, dizziness, paraesthesia, nausea, myalgia, and constipation (each in < 1%).

Permanent discontinuation of VITRAKVI for treatment emergent adverse reactions occurred in 2% of patients (2 cases each of neutrophil count decreased, ALT increased, and AST increased, 1 case each of gait disturbance, and muscular weakness). The majority of adverse reactions leading to dose reduction occurred in the first three months of treatment.

Tabulated list of adverse reactions

The safety of VITRAKVI was evaluated in 361 patients with TRK fusion‑positive cancer in one of three on‑going clinical trials, Studies 1, 2 (“NAVIGATE”), and 3 (“SCOUT”) and post‑marketing. The safety population characteristics were comprised of patients with a median age of 39.0 years (range: 0, 90) with 37% of patients being paediatric patients. Median time on treatment for the overall safety population (n=361) was 16.2 months (range: 0.1, 89.1).

The adverse drug reactions reported in patients (n=361) treated with VITRAKVI are shown in Table 3 and Table 4.

The adverse drug reactions are classified according to the System Organ Class.

Frequency groups are defined by the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), and not known (cannot be estimated from available data).

Within each frequency group, undesirable effects are presented in order of decreasing seriousness.

Table 3: Adverse drug reactions reported in TRK fusion‑positive cancer patients treated with VITRAKVI at recommended dose (overall safety population, n=361) and post‑marketing

System organ class

Frequency

All grades

Grades 3 and 4

Blood and lymphatic system disorders

Very common

Anaemia

Neutrophil count decreased (Neutropenia)

Leukocyte count decreased (Leukopenia)

Common

Platelet count decreased (Thrombocytopenia)

Anaemia

Neutrophil count decreased (Neutropenia)a

Leukocyte count decreased (Leukopenia)a

Uncommon

Platelet count decreased (Thrombocytopenia)a, b

Nervous system disorders

Very common

Dizziness

Common

Gait disturbance

Paraesthesia

Gait disturbance

Uncommon

Dizziness

Paraesthesia

Gastrointestinal disorders

Very common

Nausea

Constipation

Vomiting

Diarrhoea

Common

Dysgeusiac

Diarrhoea

Vomiting

Uncommon

Nausea

Constipation

Hepatobiliary disorders

Not known

Liver injuryd

Musculoskeletal and connective tissue disorders

Very common

Myalgia

Common

Muscular weakness

Uncommon

Myalgia

Muscular weaknessa, b

General disorders and administration site conditions

Very common

Fatigue

Uncommon

Fatigue

Investigations

Very common

Alanine aminotransferase (ALT) increased

Aspartate aminotransferase (AST) increased

Weight increased (Abnormal weight gain)

Common

Blood alkaline phosphatase increased

Alanine aminotransferase (ALT) increaseda

Aspartate aminotransferase (AST) increaseda

Weight increased (Abnormal weight gain)

Uncommon

Blood alkaline phosphatase increaseda, b

a grade 4 reactions were reported

b each grade frequency was less than <1%

c ADR dysgeusia includes the preferred terms “dysgeusia” and “taste disorder”

d includes cases with ALT/AST ≥3x ULN and bilirubin ≥2x ULN

Table 4: Adverse drug reactions reported in TRK fusion‑positive paediatric cancer patients treated with VITRAKVI at recommended dose (n=135); all grades

System organ class

Frequency

Infants and toddlers

(n=43)a

Children

(n=67)b

Adolescents

(n=25)c

Paediatric patients

(n=135)

Blood and lymphatic system disorders

Very common

Anaemia

Neutrophil count decreased (Neutropenia)

Leukocyte count decreased (Leukopenia)

Platelet count decreased (Thrombocytopenia)

Anaemia

Neutrophil count decreased (Neutropenia)

Leukocyte count decreased (Leukopenia)

Anaemia

Neutrophil count decreased (Neutropenia)

Leukocyte count decreased (Leukopenia)

Anaemia

Neutrophil count decreased (Neutropenia)

Leukocyte count decreased (Leukopenia)

Platelet count decreased (Thrombocytopenia)

Common

Platelet count decreased (Thrombocytopenia)

Platelet count decreased (Thrombocytopenia)

Nervous system disorders

Very common

Dizziness

Common

Dizziness

Dizziness

Paraesthesia

Gait disturbance

Paraesthesia

Gait disturbance

Dizziness

Paraesthesia

Gait disturbance

Gastrointestinal disorders

Very common

Nausea

Constipation

Vomiting

Diarrhoea

Nausea

Constipation

Vomiting

Diarrhoea

Nausea

Constipation

Vomiting

Diarrhoea

Nausea

Constipation

Vomiting

Diarrhoea

Common

Dysgeusia

Dysgeusia

Musculoskeletal and connective tissue disorders

Very common

Myalgia

Myalgia

Myalgia

Common

Muscular weakness

Muscular weakness

Muscular weakness

Muscular weakness

General disorders and administration site conditions

Very common

Fatigue

Fatigue

Fatigue

Fatigue

Investigations

Very common

Alanine aminotransferase (ALT) increased

Aspartate aminotransferase (AST) increased

Weight increased (Abnormal weight gain)

Blood alkaline phosphatase increased

Alanine aminotransferase (ALT) increased

Aspartate aminotransferase (AST) increased

Weight increased (Abnormal weight gain)

Blood alkaline phosphatase increased

Alanine aminotransferase (ALT) increased

Aspartate aminotransferase (AST) increased

Weight increased (Abnormal weight gain)

Blood alkaline phosphatase increased

Alanine aminotransferase (ALT) increased

Aspartate aminotransferase (AST) increased

Weight increased (Abnormal weight gain)

Blood alkaline phosphatase increased

a Infant/toddlers (28 days to 23 months): 5 grade 4 Neutrophil count decreased (Neutropenia) reactions and 2 Blood alkaline phosphatase increased reported. Grade 3 reactions included 11 cases of Neutrophil count decreased (Neutropenia), 4 cases of ALT increased, 3 cases each of Anaemia, Diarrhoea, and Weight increased (Abnormal weight gain), and 2 cases each of Blood alkaline phosphatase increased, and Vomiting and 1 case of AST increased.

b Children (2 to 11 years): 1 grade 4 Leukocytes count decreased reported. 9 reported grade 3 cases of Neutrophil count decreased (Neutropenia), 4 cases of Weight increased (Abnormal weight gain), 2 cases each of ALT increased, Anaemia, Diarrhoea, and Vomiting and 1 case each of AST increased, Gait disturbance, Paraesthesia and Myalgia.

c Adolescents (12 to <18 years): no grade 4 reactions were reported. Grade 3 reactions were reported in 1 case each of ALT increased, AST increased, Fatigue, Gait disturbance, and Muscular weakness.

Description of selected adverse reactions

Neurologic reactions

In the overall safety database (n=361), the maximum grade neurologic adverse reaction observed was grade 3 or 4 which was observed in 10 (3%) patients and included gait disturbance (4 patients, 1%), dizziness (3 patients, <1%), and paraesthesia (3 patients, <1%). The overall incidence was 20% for dizziness, 7% for paraesthesia and 5% for gait disturbance. Neurologic reactions leading to dose modification or interruptions included dizziness (1%), gait disturbance (<1%), and paraesthesia (<1%). One patient permanently discontinued the treatment due to grade 3 gait disturbance. In all cases except of one, patients with evidence of anti‑tumour activity who required a dose reduction were able to continue dosing at a reduced dose and/or schedule (see section 4.4).

Hepatotoxicity

Abnormalities of liver function tests including ALT, AST, ALP and bilirubin have been observed in patients treated with VITRAKVI.

In the overall safety database (n=361), the maximum grade transaminase elevation observed was grade 4 ALT increase in 7 patients (2%) and AST increase in 4 patients (1%). Grade 3 ALT and AST increases in 26 (7%) and 22 (6%) of patients, respectively. Majority of grade 3 elevations were transient appearing in the first three months of treatment and resolving to grade 1 by months 3‑4. Grade 2 ALT and AST increases were observed in 37 (10%) and 33 (9%) of patients, respectively, and grade 1 ALT and AST increases were observed in 173 (48%) and 177 (49%) of patients, respectively.

ALT and AST increases leading to dose modifications or interruptions occurred in 25 (7%) patients and 21 (6%) patients, respectively (see section 4.4). Two patients permanently discontinued the treatment with 1 patient due to grade 3 ALT and grade 3 AST increases.

Cases of hepatotoxicity with increases in ALT and/or AST of grade 2, 3 or 4 severity and increases in bilirubin ≥ 2x ULN have been reported. In some cases, the dose of VITRAKVI was withheld and restarted at a reduced dose, while in other cases treatment was permanently discontinued (see section 4.4).

Additional information on special populations

Paediatric patients

Of the 361 patients treated with VITRAKVI, 135 (37%) patients were from birth to < 18 years of age (n=13 from birth to < 3 months, n=4 ≥ 3 months to < 6 months, n=17 ≥ 6 months to < 12 months, n=9 ≥ 12 months to < 2 years, n=30 ≥ 2 years to < 6 years, n=37 ≥ 6 years to < 12 years, n=25 ≥ 12 years to < 18 years). The majority of adverse reactions were grade 1 or 2 in severity and were resolved without VITRAKVI dose modification or discontinuation. Adverse reactions of grade 3 or 4 in severity were generally observed more frequently in patients < 6 years of age. They were reported in 77% of patients from birth to < 3 months and in 47% of patients ≥ 3 months to < 6 years. Decreased neutrophil count has been reported to have led to study drug discontinuation, dose modification and dose interruption.

Elderly

Of the 361 patients in the overall safety population who received VITRAKVI, 69 (19%) patients were 65 years or older and 22 (6%) patients were 75 years or older. The safety profile in elderly patients (≥ 65 years) is consistent with that seen in younger patients. The adverse reaction dizziness (30% versus 28% in all adults), anaemia (36% versus 28% in all adults), diarrhoea (25% versus 23% in all adults), muscular weakness (13% versus 11% in all adults), platelet count decreased (12% versus 6% in all adults), gait disturbance (9% versus 5% in all adults), and dysgeusia (9% versus 6% in all adults) were more frequent in patients of 65 years or older.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

There is limited experience of overdose with VITRAKVI. Symptoms of overdose are not established. In the event of overdose, physicians should follow general supportive measures and treat symptomatically.